Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study) (Jason)
Sulodexide (VESSEL®) for the Prevention of Recurrent Venous Thromboembolism in Elderly Patients After a First Episode of Venous Thrombembolism
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Cristina Legnani, BSc, PhD
- Phone Number: 0039 051 2812339
- Email: c.legnani@fondazionearianna.org
Study Contact Backup
- Name: Emilia Antonucci, CR
- Phone Number: 0039 051 4291116
- Email: e.antonucci@fondazionearianna.org
Study Locations
-
-
-
Rozzano, Italy, 20089
- Recruiting
- Corrado Lodigiani
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with a first event of proximal lower extremity DVT and / or PE, idiopathic or associated with weak or removed risk factors.
- Patients aged ≥75 years at the time of enrolment
Patients with at least one of the known risk factors of bleeding (APPENDIX 1):
- Hypertension
- Renal failure
- Thrombocytopenia
- Diabetes
- Antiplatelet therapy (ASA maximum 140 mg/die)
- Frequent falls (>2 /years)
- Nonsteroidal anti-inflammatory drug
- Liver failure
- Previous Stroke
- Anemia
- Poor anticoagulant control
- Alcohol abuse
- Patients of both sexes.
- Patients who at the time of enrolment have already undergone a period of anticoagulant therapy (AT, with any medication) of at least 3 months and the therapy has not been suspended for more than 30 days.
- Patients with no other AT indications.
- Patients capable and able to provide informed consent
Exclusion Criteria:
- Patients aged <75 years at the time of the recruitment visit.
"Provoked" index event, which occurred:
- Within 3 months of surgery or major trauma,
- Bed Rest > 4 days,
- Cast / immobility within 3 months.
- Index event represented by severe PE, with life threatening risk or treated with thrombolytic therapy.
- Index event represented by isolated distal DVT or superficial venous thrombosis.
- Thrombotic event in sites other than the deep proximal veins of the lower limbs.
- Anticoagulant therapy for less than 3 months at the time of enrolment.
- Discontinuation of anticoagulant therapy for over thirty days at the time of enrolment
- Recurrent episodes of DVT ± PE
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Treatment A
Sulodexide (Vessel) 2 capsules of 250 LSU BID, for 12 months
|
2 soft capsules of Vessel® 250 LSU BID for 12 months
Other Names:
|
|
Active Comparator: Treatment B
Sulodexide (Vessel) 1 capsule of 250 LSU and 1 indistinguishable placebo capsule BID., for 12 months
|
1 soft capsule of Vessel® 250 LSU and 1 soft capsule of placebo BID for 12 months
Other Names:
Sugar pill manufactured to mimic sulodexide 250 LSU
Other Names:
|
|
Placebo Comparator: Treatment C
2 indistinguishable placebo capsules BID, for 12 months
|
Sugar pill manufactured to mimic sulodexide 250 LSU
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number and rate of patients with confirmed recurrent VTE and VTE-related death (efficacy).
Time Frame: From date of enrollment until the date of first documented event assessed up to 12 months
|
The occurrence of proximal deep vein thrombosis with or without pulmonary embolism (new or recurrent episode) wil be recorded in all patients
|
From date of enrollment until the date of first documented event assessed up to 12 months
|
|
Number and rate of major Bleeding events (defined according to International Society on Thrombosis and Haemostasis guidelines (safety)
Time Frame: From date of enrollment until the date of first documented event assessed up to 12 months
|
Fatal bleeding; intracranial; intraspinal; intraocular; pericardial; intra-articular; intramuscular with compartment syndrome; retroperitoneal,; acute clinically overt bleeding will be recorded in all patients
|
From date of enrollment until the date of first documented event assessed up to 12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of and rate of thromboembolic events
Time Frame: From date of enrollment until the date of first documented event assessed up to 12 months
|
Transient ischemic attack (TIA), Stroke, Myocardial infarction will be recorded in all patients
|
From date of enrollment until the date of first documented event assessed up to 12 months
|
|
Presence of severe post-thrombotic syndrome according to Villalta Score
Time Frame: 12 months
|
Patient with deep vein thrombosis as index event will be evaluated, at the and of follow-up, applying Villalta score, commonly used to diagnose post-thrombotic syndrome in the subacute phase of thrombosis.
The presence of venous ulcer of the leg or a score > of 15 points indicate the occurrence of severe post-thrombotic syndrome.
The maximum score is 33.
The score from 5 to 9 points indicate mild post-thrombotic syndrome and from 10 to 15 points indicate moderate post-thrombotic syndrome
|
12 months
|
|
Number and rate of non major bleeding complications
Time Frame: From date of enrollment until the date of first documented event assessed up to 12 months
|
In all patients will be recorded any sign or symptom of hemorrhage that does not fit the criteria for the definition of major bleeding but does meet at least one of the following criteria: 1)requiring medical intervention by a healthcare professional; 2) leading to hospitalization or increased level of care;3) prompting a face to face evaluation
|
From date of enrollment until the date of first documented event assessed up to 12 months
|
|
Number and rate of dead patients (overall mortality)
Time Frame: From date of enrollment until the date of first documented event assessed up to 12 months
|
VTE-related death; cardiovascular related-death; bleeding-related death; death for: cancer, infectious disease and unknown cause; sudden death will be recorded in all patients
|
From date of enrollment until the date of first documented event assessed up to 12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Corrado Lodigiani, MD,PhD, IRCCS Humanitas, Rozzano (Milano)
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Embolism and Thrombosis
- Thromboembolism
- Venous Thromboembolism
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Antimetabolites
- Hypolipidemic Agents
- Lipid Regulating Agents
- Anticoagulants
- Glucuronyl glucosamine glycan sulfate
Other Study ID Numbers
Other Study ID Numbers
- FAAI2.10.2018
- 2019-000570-33 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.